Clinical Trial: Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease

Brief Summary: Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with Cushing's disease.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: Long term efficacy (UFC) in patients with Cushing's disease [ Time Frame: at the end of the study ]

Original Primary Outcome:

Current Secondary Outcome:

  • Long term safety [ Time Frame: at the end of the study ]
  • Tolerability [ Time Frame: at the end of the study ]
  • Pharmacokinetics [ Time Frame: at the end of the study ]
  • Development of biomarker [ Time Frame: at the end of the study ]


Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 13, 2005
Date Started: August 2004
Date Completion:
Last Updated: November 15, 2016
Last Verified: November 2016